Findings of a phase II trial investigating the antiangiogenic agent pazopanib in patients with platinum-refractory advanced-stage ovarian cancer reveal that treatment with pazopanib plus paclitaxel resulted in significantly longer median progression-free survival than paclitaxel therapy alone (6.4 months versus 3.5 months; P = 0.00042). Pazopanib treatment, although well-tolerated, resulted in more severe adverse events than paclitaxel alone. These findings indicate a need to test this agent in phase III trials.
References
Pignata, S. et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 10.1016/S1470-2045(15)70115-4
Rights and permissions
About this article
Cite this article
Pazopanib is an effective treatment of ovarian cancer. Nat Rev Clin Oncol 12, 374 (2015). https://doi.org/10.1038/nrclinonc.2015.82
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.82